An interventional study of EsoGLOVE and Graded Repetitive Arm Supplementary Program (GRASP) in Stroke, sponsored by Alexandra Hospital. Completed at 2 sites in Singapore. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Alexandra Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Stroke with a site in Singapore — 16 open to participants now, 21 under way, 1 of them phase 3. Stroke · Singapore.
Among the 104 studies in Stroke with a site in Singapore, this one is the 38th largest by enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2023, is one of 58 with no phase, and was the 78th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →16 of the 104 studies in Stroke with a site in Singapore are open now. Recruiting first, the newest first:
The Hong Kong Polytechnic University · Sites in Singapore, Hong Kong
Ages 21–79 · Healthy volunteers
Tan Tock Seng Hospital · Sites in Singapore
Ages 21–80
National University of Singapore · Sites in Singapore
Ages 21–65
Mah Shi Min · Sites in Singapore
Ages 21–99
Tan Tock Seng Hospital · Sites in Singapore
Ages 50+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 21 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 15 · Phase 4 7
First in 1998; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 51 across the 86 interventional studies, 300 across the 17 observational. Of the 79 that completed or were terminated, 16 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 104 have an industry lead sponsor. The 10 most frequent:
Alexandra Hospital is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Alexandra Hospital has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Stroke with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06999876National University Health System, SingaporeThe Effect of Combined Transcranial Pulse Current Stimulation (tPCS) and Transcutaneous Electrical Nerve Stimulation (TENS) on Lower Limb Motor Function in Subacute to Chronic Stroke Patients With Hemiplegia (COMPENSATOR-Stroke) | 2026-11-30 |
| NCT06704997Tan Tock Seng HospitalMachine Learning to Predict Factors Affecting Rehabilitation Length of Stay and Healthcare Costs for Neurological Rehabilitation | 2026-12-31 |
| NCT06409351Singapore General HospitalMulti-modal Training Program to Promote Physical Activity After Stroke | 2026-12-31 |
| NCT06073106Tan Tock Seng HospitalTargeting Osteosarcopaenia and Multimorbidity for Frailty Prevention | 2027-01 |
| NCT07122752Tan Tock Seng HospitalFeasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy | 2027-08-29 |
Add all 6 to your calendar (.ics) → With an account.
Among the 104 studies in Stroke with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This proposed research aims to assess the efficacy and feasibility of the EsoGLOVE in the inpatient rehabilitation setting. 1. Understanding the ability of the EsoGLOVE in providing exercise and assisting stroke patients with completing hand functional tasks, eventually improves patients' motor function and neural recovery.2. To generate evidence on this innovative device and further deploy it in clinical practice. A Health Technology Assessment (HTA) will be generated from this study to evaluate the cost-effectiveness of the intervention.
This project proposes a study of 130 subjects in inpatient settings who have sustained their first-ever stroke prior to clinical trial enrolment. Participants are randomly assigned to 2 groups (EsoGLOVE group and GRASP group). The randomization method: A block randomization with a randomly varying block size. The study will last 12 weeks (3 weeks of intervention during hospitalization + 12th-week outpatient follow-up post-discharge). The subjects will use the study device about 15 times and be followed up for 3 weeks during hospitalization.
The subjects will need to visit the doctor's office 1 time (outpatient follow-up post-discharge) in the course of the study.During the hospitalization, the stroke patients (subjects) will receive intensive stroke rehabilitation as per normal, which will be daily physiotherapy and occupational therapy as a part of standard care as per stroke rehabilitation. On top of the standard care (daily Inpatient OT Rehabilitation), the EsoGLOVE subjects will receive EsoGLOVE training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day. While the GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.In the case of early discharge or withdrawal for any reason before the 3-week intervention is completed, the subjects will no longer participate in this study and no study-related activities will be performed on the subjects. The subjects' right to receive standard care will remain the same as per hospital guidelines and will not be affected. This is applicable to both groups. With minimal compliance rate (10 sessions) for continuing the study, regardless of the subjects' discharge before 3 weeks, otherwise (less than or equal to 9 sessions) subjects will be withdrawn at the day of discharge or withdrawal. The 12th-week outpatient follow-up post-discharge at the clinic will coincide with the subject's standard care follow-up visit.The Health Technology Assessment (HTA) is conducted by the study team using explicit analytical frameworks, clinical outcomes, epidemiological data amp; statistics, health economic information, and study methodology. The assessment includes building evidence on the qualities and costs of health interventions (cost-effectiveness), identifying the direct amp; indirect medical costs in the current healthcare system, capturing the clinical outcomes of interventions, synthesizing health research findings of the effectiveness of different health interventions, evaluating the economic implications and analyzing the cost-effectiveness of the intervention.It is unlikely this study might unintentionally come to know of new information (Incidental Finding) about the health condition from the assessment (Fugl-Meyer Assessment - Upper Extremity) of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The EsoGLOVEGroup subjects will receive EsoGLOVE training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day
Device: EsoGLOVE
The GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day
Other: Graded Repetitive Arm Supplementary Program (GRASP)
The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVE training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day, up to 15 sessions. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).
Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
Fugl-Meyer Assessment for the Upper Extremity
upper limb impairment scale ranged from 0-66 with higher score indicating better outcome
Time frame: Baseline, immediately post-intervention and 3 months post-intervention
Stroke Impact Scale-16
consists of 16 items from the 4 physical domains (strength, hand function, mobility, and ADL/IADL) ranged from 16 to 80 with higher score indicating better outcome
Time frame: Baseline, immediately post-intervention and 3 months post-intervention
Stroke Upper Limb Capacity Scale
Activities limitation of upper limb ranged 0 to10 with higher score indicating better outcome
Time frame: Baseline, immediately post-intervention and 3 months post-intervention
Duruoz Hand Index
self-reported upper limb function ranged 0 to 90 with higher score indicating worse outcome
Time frame: Baseline, immediately post-intervention and 3 months post-intervention
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Aug 2025, 25 months.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 25 months is close to that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexandra Hospital